Table S VII.

Analysis of the evolution of the LP of the different generic Dasatinib medicines approved in Spain with respect to the innovative drug.

Drug type & company	CIPM approval date	Marketing authorization date	CIPM LP (€/mg)*	Interval since 1st Gx approval by CIPM (years)	Price difference vs innovative price	Price difference vs 1st Gx approved by CIPM
Innovative (BMS)	07/02/2009	NA	1.559	NA	NA	NA
Generic 1 (Teva)	30/10/2019	01/05/2019	0.49	0	-69%	0%
Generic 2 (Stada)	28/02/2021	01/07/2020	0.472	1.3	-70%	-4%

* In the case of the innovative medicine, the authorized PVL at the time of marketing of the first generic drug is indicated.